



CLOSURE OF ENTITLEMENT OFFER AND NOTIFICATION OF SHORTFALL

Perth, Australia, 12 December 2018: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) is pleased to announce that the non-renounceable Entitlement Offer (**Offer**) to raise approximately \$3.3 million (before costs) closed at 2:00pm (WST) on Monday, 10 December 2018 as per the terms of the Offer.

The Company has received applications to subscribe for 59,141,273 new Shares from eligible shareholders under the Offer raising \$1,184,484.26.

All new shares issued under the Entitlement Issue will rank equally in all respects with the existing fully paid ordinary shares of the Company.

As outlined in the Offer Document the Company entered into a mandate letter (**Mandate**) with Merchant Corporate Advisory Pty Ltd (**Merchant**) who have agreed under the Mandate to subscribe for and/or place all Shortfall Shares under the Offer.

- ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg
Chairman
E peter@bard1.com

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company's pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients' lives.